The HiBiT Target Cell Killing platform provides a bioluminescent system for precisely measuring direct and bystander cytotoxicity in antibody-drug conjugate development. This streamlined workflow allows biotech developers to distinguish between specific target cell death and neighboring antigen-negative cell killing in complex co-cultures without manual staining or washing. Professionals can now more accurately characterize linker-payload chemistry to optimize therapeutic coverage while minimizing damage to healthy tissue.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





